Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
NCT03716505 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
Conditions Studied
Interventions
- DEVICE gammaCore Sapphire active
- DEVICE gammaCore Sapphire Sham
Study Locations (20)
California
- The Research Center of Southern California — Carlsbad
- Stanford University Medical Center Hoover Pavilion — Palo Alto
- UCSF Headache Center — San Francisco
- California Medical Clinic for Headache — Santa Monica
Connecticut
- New England Institute for Neurology and Headache — Stamford
- Hartford HealthCare Headache Center — West Hartford
Illinois
- Diamond Headache Clinic — Chicago
- NorthShore Ambulatory Care Center — Glenview
Louisiana
- Crescent City Headache and Neurology Center — Chalmette
- Ochsner North Shore Medical Center — Covington
Missouri
- StudyMetrix, LLC — City of Saint Peters
- Clinvest Research — Springfield
Arizona
- Mayo Clinic — Scottsdale
Colorado
- Summit Headache and Neurologic Institute, PC — Englewood
Florida
- University of Miami, Miller School of Medicine — Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2020-09-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03716505
The ClinicalTrials.gov registry entry for NCT03716505 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ElectroCore, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions — of which gammaCore Sapphire active is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03716505 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Connecticut, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03716505 about?
NCT03716505 is a clinical study titled "Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines". The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
What is the current status of trial NCT03716505?
This trial is currently completed. It is a NA study. The enrollment target is 231 participants. The study started on 2018-11-02. Estimated completion is 2020-09-09.
What conditions does trial NCT03716505 study?
This clinical trial studies the following conditions: Migraine Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03716505?
The interventions under investigation include: gammaCore Sapphire active (DEVICE), gammaCore Sapphire Sham (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03716505?
This trial is sponsored by ElectroCore, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03716505 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.